Abstract
Structure- and property-based drug design is an integral part of modern drug discovery, enabling the design of compounds aimed at improving potency and selectivity. However, building molecules using desktop modeling tools can easily lead to poor designs that appear to form many favorable interactions with the protein’s active site. Although a proposed molecule looks good on screen and appears to fit into the protein site X-ray crystal structure or pharmacophore model, doing so might require a high-energy small molecule conformation, which would likely be inactive. To help scientists make better design decisions, we have built integrated, easy-to-use, interactive software tools to perform docking experiments, de novo design, shape and pharmacophore based database searches, small molecule conformational analysis and molecular property calculations. Using a combination of these tools helps scientists in assessing the likelihood that a designed molecule will be active and have desirable drug metabolism and pharmacokinetic properties. Small molecule discovery success requires project teams to rapidly design and synthesize potent molecules with good ADME properties. Empowering scientists to evaluate ideas quickly and make better design decisions with easy-to-access and easy-to-understand software on their desktop is now a key part of our discovery process.
Similar content being viewed by others
References
Lee M-L, Aliagas I, Dotson J et al (2012) DEGAS: sharing and tracking target compound ideas with external collaborators. J Chem Inf Model 52:278–284. doi:10.1021/ci2003297
Benchware 3D Explorer Version 2.3 Tripos, Saint Louis. http://www.certara.com/products/molmod/bw3de. Accessed 16 Nov 2013
Molecular operating environment (MOE) Version 2012.10 Chemical Computing Group Inc., Quebec. www.chemcomp.com. Accessed 16 Nov 2013
The PyMOL Molecular Graphics System Version 1.5 Schrodinger LLC, New York. www.pymol.org. Accessed 16 Nov 2013
FastROCS Version 1.1 OpenEye Scientific Software, Sante Fe. www.eyesopen.com/fastrocs. Accessed 16 Nov 2013
Nicholls A, McGaughey GB, Sheridan RP et al (2010) Molecular shape and medicinal chemistry: a perspective. J Med Chem 53:3862–3886. doi:10.1021/jm900818s
Liang J, Tsui V, Van Abbema A et al (2013) Lead identification of novel and selective TYK2 inhibitors. Eur J Med Chem 67:175–187. doi:10.1016/j.ejmech.2013.03.070
Liang J, Van Abbema A, Balazs M et al (2013) Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J Med Chem 56:4521–4536. doi:10.1021/jm400266t
Pipeline Pilot Version 7.0 Accelrys, San Diego. www.accelrys.com/products/pipeline-pilot. Accessed 16 Nov 2013
Glide Version 6.0 Schrodinger LLC, New York. www.schrodinger.com/productpage/14/5/. Accessed 16 Nov 2013
Friesner RA, Banks JL, Murphy RB et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749. doi:10.1021/jm0306430
Warren GL, Andrews CW, Capelli A-M et al (2006) A critical assessment of docking programs and scoring functions. J Med Chem 49:5912–5931. doi:10.1021/jm050362n
Warren GL, Do TD, Kelley BP et al (2012) Essential considerations for using protein–ligand structures in drug discovery. Drug Discov Today 17:1270–1281. doi:10.1016/j.drudis.2012.06.011
Liebeschuetz J, Hennemann J, Olsson T, Groom CR (2012) The good, the bad and the twisted: a survey of ligand geometry in protein crystal structures. J Comput Aided Mol Des 26:169–183. doi:10.1007/s10822-011-9538-6
MoKa Molecular Discovery, Perugia. www.moldiscovery.com/soft_moka.php. Accessed 16 Nov 2013
GRID molecular discovery, Perugia. www.moldiscovery.com/soft_moka.php. Accessed 3 Jan 2015
Wan PTC, Garnett MJ, Roe SM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867
Schneider EV, Böttcher J, Blaesse M et al (2011) The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. J Mol Biol 412:251–266. doi:10.1016/j.jmb.2011.07.020
Firestein R, Bass AJ, Kim SY et al (2008) CDK8 is a colorectal cancer oncogene that regulates |[bgr]|-catenin activity. Nature 455:547–551. doi:10.1038/nature07179
Firestein R, Hahn WC (2009) Revving the throttle on an oncogene: cDK8 takes the driver seat. Cancer Res 69:7899–7901. doi:10.1158/0008-5472.CAN-09-1704
Davis MI, Hunt JP, Herrgard S et al (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29:1046–1051. doi:10.1038/nbt.1990
Liu Y, Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2:358–364. doi:10.1038/nchembio799
ROCS Version 3.1.2 OpenEye Scientific Software, Sante Fe. www.eyesopen.com/rocs. Accessed 16 Nov 2013
McGaughey GB, Sheridan RP, Bayly CI et al (2007) Comparison of topological, shape, and docking methods in virtual screening. J Chem Inf Model 47:1504–1519. doi:10.1021/ci700052x
Hill AP, Young RJ (2010) Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. Drug Discov Today 15:648–655. doi:10.1016/j.drudis.2010.05.016
Hann MM, Keserű GM (2012) Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat Publ Group 11:355–365. doi:10.1038/nrd3701
Ortwine DF, Aliagas I (2013) Physicochemical and DMPK in silico models: facilitating their use by medicinal chemists. Mol Pharm 10:1153–1161. doi:10.1021/mp3006193
Aliagas I A (2015, accepted) Probabilistic method to report predictions from a human liver microsome stability QSAR model: a practical tool for drug discovery. J Comput Aided Mol Des 29(4):327–338. doi:10.1007/s10822-015-9838-3
Price DA, Blagg J, Jones L et al (2009) Physicochemical drug properties associated with in vivotoxicological outcomes: a review. Expert Opin Drug Metab Toxicol 5:921–931. doi:10.1517/17425250903042318
Wager TT, Hou X, Verhoest PR, Villalobos A (2010) Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 1:435–449. doi:10.1021/cn100008c
Lipinski C, Lombardo F, Dominy B, Feeney P (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25
Liu L, Halladay JS, Shin Y et al (2011) Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitor. Drug Metab Dispos 39:1840–1849. doi:10.1124/dmd.111.040840
Heffron TP, Salphati L, Alicke B et al (2012) The Design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α. J Med Chem 55:8007–8020. doi:10.1021/jm300867c
Estrada AA, Liu X, Baker-Glenn C et al (2012) Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem 55:9416–9433. doi:10.1021/jm301020q
Gobbi A, Lee M-L Aestel Open source software San Francisco. http://sourceforge.net/projects/aestel/. Accessed 16 Nov 2013
OEChem Toolkit OpenEye Scientific Software, Sante Fe. www.eyesopen.com/oechem-tk. Accessed 16 Nov 2013
Hawkins PCD, Skillman AG, Warren GL et al (2010) Conformer generation with OMEGA: algorithm and validation using high quality structures from the protein databank and Cambridge structural database. J Chem Inf Model 50:572–584. doi:10.1021/ci100031x
Grapheme Toolkit OpenEye Scientific Software, Sante Fe. www.eyesopen.com/grapheme-tk. Accessed 16 Nov 2013
Hao M-H, Haq O, Muegge I (2007) Torsion angle preference and energetics of small-molecule ligands bound to proteins. J Chem Inf Model 47:2242–2252. doi:10.1021/ci700189s
Halgren TA (1998) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 17:490–519. doi:10.1002/(SICI)1096-987X(199604)17:5/6<490:AID-JCC1>3.0.CO;2-P
Bissantz C, Kuhn B, Stahl M (2010) A medicinal chemist’s guide to molecular interactions. J Med Chem 53:5061–5084. doi:10.1021/jm100112j
Jones G, Willett P, Glen RC et al (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727–748. doi:10.1006/jmbi.1996.0897
Vortex Dotmatics, Bishops Stortford. www.dotmatics.com/products/vortex Accessed 16 Nov 2013
Spotfire TIBCO Software, Boston. www.spotfire.tibco.com. Accessed 16 Nov 2013
CMR Biobyte Corp, Claremont. www.biobyte.com. Accessed 16 Nov 2013
Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714–3717. doi:10.1021/jm000942e
Acknowledgments
We thank the late Dr. Warren DeLano for help with creating custom menus in PyMOL, and for implementing a webserver in PyMOL that enabled integration with external programs. We also thank Dr. Matthias Keil, Dr. Howard Feldman and their Chemical Computing Group colleagues for implementing features in MOE to enable integration with external software tools. Lastly, we thank Genentech colleagues for providing useful feedback.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Feng, J.A., Aliagas, I., Bergeron, P. et al. An integrated suite of modeling tools that empower scientists in structure- and property-based drug design. J Comput Aided Mol Des 29, 511–523 (2015). https://doi.org/10.1007/s10822-015-9845-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-015-9845-4